Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Immunovant Inc (IMVT)

Immunovant Inc (IMVT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
14.84 -0.63 (-4.07%) 04/16/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 14.84 unch (unch) 16:35 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
14.50
Day High
15.78
Open 15.78
Previous Close 15.47 15.47
Volume 1,978,600 1,978,600
Avg Vol 2,457,515 2,457,515
Stochastic %K 40.72% 40.72%
Weighted Alpha -55.35 -55.35
5-Day Change -0.06 (-0.40%) -0.06 (-0.40%)
52-Week Range 12.72 - 34.47 12.72 - 34.47
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,626,900
  • Shares Outstanding, K 169,861
  • Annual Sales, $ 0 K
  • Annual Income, $ -259,340 K
  • EBIT $ -405 M
  • EBITDA $ -405 M
  • 60-Month Beta 0.81
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.43

Options Overview Details

View History
  • Implied Volatility 95.46% ( -3.03%)
  • Historical Volatility 77.81%
  • IV Percentile 85%
  • IV Rank 53.65%
  • IV High 159.16% on 03/03/25
  • IV Low 21.73% on 08/23/24
  • Put/Call Vol Ratio 1.21
  • Today's Volume 84
  • Volume Avg (30-Day) 1,804
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 32,619
  • Open Int (30-Day) 43,122

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.72
  • Number of Estimates 10
  • High Estimate -0.56
  • Low Estimate -0.86
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.72 +16.67%
on 04/09/25
Period Open: 19.52
20.44 -27.40%
on 03/19/25
-4.68 (-23.98%)
since 03/14/25
3-Month
12.72 +16.67%
on 04/09/25
Period Open: 23.80
24.74 -40.02%
on 01/17/25
-8.96 (-37.65%)
since 01/16/25
52-Week
12.72 +16.67%
on 04/09/25
Period Open: 30.40
34.47 -56.95%
on 09/06/24
-15.56 (-51.18%)
since 04/16/24

Most Recent Stories

More News
Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

IMVT : 14.84 (-4.04%)
Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

IMVT : 14.84 (-4.04%)
Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

IMVT : 14.84 (-4.04%)
Immunovant Announces $450 Million Private Placement

IMVT : 14.84 (-4.04%)
Insider Sale: Chief Legal Officer of $IMVT (IMVT) Sells 3,650 Shares

Mark S. Levine, the Chief Legal Officer of $IMVT ($IMVT), sold 3,650 shares of the company on 11-20-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.1% of...

IMVT : 14.84 (-4.04%)
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

IMVT : 14.84 (-4.04%)
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

IMVT : 14.84 (-4.04%)
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond

These five biotech companies could have a lot of room to run.

IMVT : 14.84 (-4.04%)
BGNE : 184.71 (+0.49%)
CRSP : 37.78 (-3.00%)
ARGX : 587.59 (-2.94%)
AMGN : 282.64 (-4.29%)
Why Immunovant Stock Is Bolting Higher Today

The company may have best-in-class autoimmune disease therapy under its roof.

IMVT : 14.84 (-4.04%)
JNJ : 153.91 (+0.19%)
ARGX : 587.59 (-2.94%)
ROIV : 10.02 (-0.40%)
Stocks Tumble as Confidence in the U.S. Economic Outlook Wanes

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -1.47%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -1.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

IMVT : 14.84 (-4.04%)
GOOGL : 153.33 (-1.91%)
AMAT : 138.19 (-4.99%)
AAPL : 194.27 (-3.89%)
AVGO : 174.61 (-2.43%)
CNP : 36.78 (-1.02%)
ADI : 175.93 (-2.01%)
TXN : 146.55 (-3.06%)
$IUXX : 18,257.64 (-3.04%)
ASML : 634.93 (-7.06%)
MSFT : 371.61 (-3.66%)
ZNM25 : 111-055 (-0.22%)
ESSA Pharma to Present at the JonesHealthcare Seaside Summit

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Jefferies Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
U.S. CPI, Fed Decision in News Next Wee

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q2) Reported EPS for $1.05, ...

PFX : 51.09 (+0.01%)
ORCL : 129.76 (-3.12%)
DOL.TO : 169.59 (+0.72%)
JCI : 76.66 (-2.46%)
COST : 967.75 (-0.94%)
BLBD : 33.25 (-1.34%)
TCL-A.TO : 17.46 (-0.06%)
LEN : 102.76 (-2.21%)
NDSN : 180.69 (-1.31%)
PLAB : 17.78 (-1.17%)
ADBE : 344.19 (-1.77%)
MANU : 13.80 (-1.78%)
ESSA Pharma to Present at the JonesHealthcare Seaside Summit

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Jefferies Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
U.S. CPI, Fed Decision in News Next Wee

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q2) Reported EPS for $1.05, ...

PFX : 51.09 (+0.01%)
ORCL : 129.76 (-3.12%)
DOL.TO : 169.59 (+0.72%)
JCI : 76.66 (-2.46%)
COST : 967.75 (-0.94%)
BLBD : 33.25 (-1.34%)
TCL-A.TO : 17.46 (-0.06%)
LEN : 102.76 (-2.21%)
NDSN : 180.69 (-1.31%)
PLAB : 17.78 (-1.17%)
ADBE : 344.19 (-1.77%)
MANU : 13.80 (-1.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing batoclimab, a novel, fully-human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The...

See More

Key Turning Points

3rd Resistance Point 16.86
2nd Resistance Point 16.32
1st Resistance Point 15.58
Last Price 14.84
1st Support Level 14.30
2nd Support Level 13.76
3rd Support Level 13.02

See More

52-Week High 34.47
Fibonacci 61.8% 26.16
Fibonacci 50% 23.60
Fibonacci 38.2% 21.03
Last Price 14.84
52-Week Low 12.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro

Info When You Need It Most.

Barchart Premier is one of the most powerful tools in the investment world. Come see why so many subscribers love it — and try it risk-free for 30 days.